PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sodium chloride - Mobilisation of lower respiratory tract secretions
PAD Profile : Sodium chloride - Mobilisation of lower respiratory tract secretions
Keywords :
nebulised saline, hypertonic saline
Traffic Light Status
Status 1 of 4.
Status :
Blue
Important
Formulations :
- Inhalation
- Nebules
Important Information :
0.9% sodium chloride in 2.5ml unit dose ampoules.
OptimiseRx will be used to inform Primary Care prescribers of the locally preferred, cost effective brand.
Primary Care may prescribe on recommendation from the Respiratory Care Team who will ensure that patients have had suitable training and trial of equipment to ensure safe use.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 4.
Status :
Red
Important
Formulations :
- Inhalation
- Nebules
Important Information :
3% hypertonic sodium chloride
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 3 of 4.
Status :
Red
Important
Formulations :
- Inhalation
- Nebules
Important Information :
6% hypertonic sodium chloride
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 4 of 4.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 November 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
Associated BNF Codes
12. Ear, Nose and Oropharynx
12.02.02. Topical nasal decongestants